Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11337927 Sustained-release dosage forms of ruxolitinib

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

William V. Williams0

Yong Ni0

Bhavnish Parikh0

Krishnaswamy Yeleswaram0

Susan Erickson-Viitanen0

Date of Patent

May 24, 2022

0

Patent Application Number

170989130

Date Filed

November 16, 2020

0

Patent Citations

US Patent 11214573 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors

US Patent 10166191 Sustained-release dosage forms of ruxolitinib

US Patent 10398699 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors

US Patent 10513522 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors

US Patent 10561616 Sustained release dosage forms for a JAK1 inhibitor

US Patent 10639310 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors

US Patent 10640506 Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors

US Patent 10766900 Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof

...

Patent Citations Received

US Patent 12071439 Process and intermediates for preparing a JAK inhibitor

0

US Patent 11576864 Sustained-release dosage forms of ruxolitinib

US Patent 11744832 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors

US Patent 11833155 Combination therapy for treatment of myeloproliferative neoplasms

0

US Patent 11905292 Process and intermediates for preparing a JAK inhibitor

0

US Patent 11576865 Sustained-release dosage forms of ruxolitinib

Patent Primary Examiner

Umamaheswari Ramachandran

0

CPC Code

0

0

The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11337927 Sustained-release dosage forms of ruxolitinib

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.